Jupiter Neurosciences, Inc.
NASDAQ: JUNS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christer Rosen
- Employees
- 4
- Headquarters
- Jupiter, United States
- IPO year
- 2022
- Market cap
- $9.2M
- Website
- https://www.jupiterorphan.com
Loading JUNS…
Loading profile data…Frequently asked questions about JUNS
What does Jupiter Neurosciences, Inc. (JUNS) do?
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich'...
Where does JUNS trade?
Jupiter Neurosciences, Inc. (JUNS) trades on the NASDAQ Capital Market.
What sector is JUNS in?
Jupiter Neurosciences, Inc. (JUNS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Jupiter Neurosciences, Inc.?
Christer Rosen is the chief executive officer of Jupiter Neurosciences, Inc. (JUNS).
Where is Jupiter Neurosciences, Inc. headquartered?
Jupiter Neurosciences, Inc. is headquartered in United States.
Does JUNS pay a dividend?
Jupiter Neurosciences, Inc. (JUNS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did JUNS go public?
Jupiter Neurosciences, Inc. (JUNS) completed its initial public offering in 2022.